150 related articles for article (PubMed ID: 24939652)
1. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo.
Poirier A; Cascais AC; Bader U; Portmann R; Brun ME; Walter I; Hillebrecht A; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1411-22. PubMed ID: 24939652
[TBL] [Abstract][Full Text] [Related]
2. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
[TBL] [Abstract][Full Text] [Related]
3. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.
Cook JA; Feng B; Fenner KS; Kempshall S; Liu R; Rotter C; Smith DA; Troutman MD; Ullah M; Lee CA
Mol Pharm; 2010 Apr; 7(2):398-411. PubMed ID: 20025245
[TBL] [Abstract][Full Text] [Related]
4. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
5. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
6. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.
Sugimoto H; Matsumoto S; Tachibana M; Niwa S; Hirabayashi H; Amano N; Moriwaki T
J Pharm Sci; 2011 Sep; 100(9):4013-23. PubMed ID: 21678427
[TBL] [Abstract][Full Text] [Related]
7. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
8. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein.
Iwaki K; Sakaeda T; Kakumoto M; Nakamura T; Komoto C; Okamura N; Nishiguchi K; Shiraki T; Horinouchi M; Okumura K
J Pharm Pharmacol; 2006 Dec; 58(12):1617-22. PubMed ID: 17331325
[TBL] [Abstract][Full Text] [Related]
10. Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1.
Hutter V; Chau DY; Hilgendorf C; Brown A; Cooper A; Zann V; Pritchard DI; Bosquillon C
Eur J Pharm Biopharm; 2014 Jan; 86(1):74-82. PubMed ID: 23816640
[TBL] [Abstract][Full Text] [Related]
11. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
Lee CA; Kalvass JC; Galetin A; Zamek-Gliszczynski MJ
Clin Pharmacol Ther; 2014 Sep; 96(3):298-301. PubMed ID: 25141954
[TBL] [Abstract][Full Text] [Related]
12. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
13. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
14. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
15. Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux.
Jutabha P; Wempe MF; Anzai N; Otomo J; Kadota T; Endou H
Pharmacol Res; 2010 Jan; 61(1):76-84. PubMed ID: 19631272
[TBL] [Abstract][Full Text] [Related]
16. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
17. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
18. Assessment of P-glycoprotein substrate and inhibition potential of test compounds in MDR1-transfected MDCK cells.
C L Lam K; Rajaraman G
Curr Protoc Pharmacol; 2012 Sep; Chapter 7():Unit7.13. PubMed ID: 22948850
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
[TBL] [Abstract][Full Text] [Related]
20. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
